SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer

Inclusion Criteria: Histologically confirmed colorectal adenocarcinoma, initially diagnosed or recurred Peritoneal metastasis of colorectal cancer At least one uni-dimensional measurable lesion by RECIST criteria Age 18 to 80 years old Estimated life expectancy ≥3 months ECOG performance status ≤2 Adequate bone marrow function (WBCs ≥ 4,000/µL or absolute neutrophil count ≥ 1,500/µL, platelets ≥ 100,000/µL) Adequate kidney function (creatinine \< 1.5 mg/dL) Adequate liver function (bilirubin \< 2.0 mg/dL, transaminase levels \<2.5 times the upper normal limit) Written informed consent Exclusion Criteria: Other tumor type than adenocarcinoma Previous history of chemotherapy (exception : neoadjuvant or adjuvant chemotherapy without oxaliplatin) Presence of CNS metastasis, psychosis, or seizure Obvious bowel obstruction Evidence of serious gastrointestinal bleeding Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri Pregnant or lactating women, women of childbearing potential not employing adequate contraception Other serious illness or medical conditions